Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective

BACKGROUND: Pembrolizumab monotherapy and nivolumab in combination with ipilimumab are US FDA-approved first-line (1L) regimens for patients with metastatic non-small cell lung cancer (NSCLC) without epidermal growth factor receptor or anaplastic lymphoma kinase genomic aberrations and with a progra...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Nan, Insinga, Ralph, Burke, Thomas, Lopes, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611160/
https://www.ncbi.nlm.nih.gov/pubmed/34292540
http://dx.doi.org/10.1007/s41669-021-00288-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611160/
https://www.ncbi.nlm.nih.gov/pubmed/34292540
http://dx.doi.org/10.1007/s41669-021-00288-1

Ejemplares similares